The U.S. Department of Health and Human Services has announced that COVID-19 Emergency Use Authorization declarations for certain medical devices will end in 180 days. HHS said the determinations were signed by the secretary and apply to drugs and biological products with a later termination timeline of 12 months. HHS framed the end of EUA authority as a move to reinforce that emergency powers are “temporary and targeted,” noting that FDA approvals and clearances through standard regulatory pathways have increased while reliance on EUA products has declined. HHS also cited an FDA EUA history for in vitro diagnostics—373 EUAs for molecular and antigen tests between 2020 and 2023. For manufacturers and clinical labs, the shift means operational planning can transition from emergency supply frameworks toward stable post-pandemic compliance expectations.